Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767776 | 0.83 | SLC7A5 (0.55) | CYP4F2CYP4A11ALDH1A1LMNAKDM4E | |
| SCHEMBL12255149 | 0.81 | SIRT2 (0.52) | SIRT2PTPN1CYP4F2CYP4A11TDP1 | |
| SCHEMBL30655576 | 0.81 | SPR (0.57) | SIRT2CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL1124591 | 0.81 | SPR (0.57) | SIRT2CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL1410879 | 0.81 | SIRT2 (0.52) | SIRT2PTPN1CYP4F2CYP4A11TDP1 | |
| SCHEMBL19540906 | 0.81 | SIRT2 (0.52) | SIRT2PTPN1CYP4F2CYP4A11TDP1 | |
| SCHEMBL1107166 | 0.81 | SIRT2 (0.52) | SIRT2CYP4F2CYP4A11TDP1ALDH1A1 | |
| SCHEMBL28655132 | 0.81 | SLC7A5 (0.57) | SIRT2PTPN1CYP4F2CYP4A11TDP1 | |
| SCHEMBL972580 | 0.80 | SIRT2 (0.51) | SIRT2PTPN1CYP4F2CYP4A11TDP1 | |
| SCHEMBL7716761 | 0.80 | SIRT2 (0.51) | SIRT2PTPN1CYP4F2CYP4A11TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329668-B2 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1735280-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005115983-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | SIRT2 308/4885PTPN1 376/4885CYP4F2 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.